|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...8990919293949596979899...156157» |
- Clinical: Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients. (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=106, Recruiting, Sponsor: Medical University of Warsaw
- RSLV-132 / Resolve
New P2 trial: Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jul 18, 2014
P2, N=32, Recruiting, Sponsor: Resolve Therapeutics
- Enrollment open, Trial initiation date: Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study) (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=40, Recruiting, Sponsor: Children's Hospital of Eastern Ontario
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) (clinicaltrials.gov) - Jul 18, 2014
P3, N=200, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jul 2014 Recruiting --> Active, not recruiting
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: ACT-RAY: A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment (clinicaltrials.gov) - Jul 18, 2014
P3, N=556, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Aug 2010
- | Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial termination: A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) (clinicaltrials.gov) - Jul 17, 2014
P3, N=173, Terminated, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Aug 2010 Active, not recruiting --> Terminated; Trial has failed to meet primary - and major secondary endpoints
- andecaliximab (GS-5745) / Gilead
Enrollment open, P1 data, PK/PD data: Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 17, 2014
P1, N=20, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Terminated; Trial has failed to meet primary - and major secondary endpoints Not yet recruiting --> Recruiting
- Enrollment open: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=12, Recruiting, Sponsor: University of Cambridge
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Jul 17, 2014
P1, N=30, Recruiting, Sponsor: GE Healthcare
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Dec 2015
- famotidine/ibuprofen / Generic mfg.
Trial primary completion date: Open-label Safety and Pharmacokinetic Study of DUEXIS (clinicaltrials.gov) - Jul 17, 2014
P4, N=30, Recruiting, Sponsor: Horizon Pharma, Inc.
Trial primary completion date: Sep 2014 --> Dec 2015 Trial primary completion date: Apr 2014 --> Oct 2015
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P1 trial: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) - Jul 17, 2014
P1, N=0, Not yet recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2014
P1, N=32, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 17, 2014
P1, N=39, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: "Medikidz Explain JIA Comic Book- Hebrew" (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Rabin Medical Center
- | zoledronic acid / Generic mfg.
Enrollment open: AZAR: Zoledronic Acid in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 16, 2014
P3, N=94, Recruiting, Sponsor: Carmen Gómez-Vaquero
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial termination, Combination therapy: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 16, 2014
P2, N=3, Terminated, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Completed --> Terminated; Study was terminated after enrollment of 3 participants due to recruitment difficulties.
- Enrollment open, Trial initiation date, Trial primary completion date: Feasibility Study of PID Versus MPC and HMS (clinicaltrials.gov) - Jul 16, 2014
P0, N=20, Recruiting, Sponsor: Sansum Diabetes Research Institute
Completed --> Terminated; Study was terminated after enrollment of 3 participants due to recruitment difficulties. Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> Jul 2014 | Trial primary completion date: May 2014 --> Jan 2015
- atorvastatin / Generic mfg.
Trial completion: Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Jul 16, 2014
P2, N=42, Completed, Sponsor: Children's Hospital of Philadelphia
Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> Jul 2014 | Trial primary completion date: May 2014 --> Jan 2015 Active, not recruiting --> Completed
- Clinical: Educational Needs of Patients With Systemic Vasculitis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=386, Completed, Sponsor: University of South Florida
- | Trial completion: An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=24, Completed, Sponsor: Parion Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Davictrel (etanercept biosimilar) / Hanwha Chem
Trial completion, Combination therapy: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients (clinicaltrials.gov) - Jul 15, 2014
P3, N=294, Completed, Sponsor: Hanwha Chemical
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 15, 2014
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jul 2016
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2014
P3, N=12, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Sep 2014
- Clinical: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=2500, Not yet recruiting, Sponsor: International Islamic University Malaysia
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate (clinicaltrials.gov) - Jul 15, 2014
P2, N=140, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2015 --> Sep 2014 Not yet recruiting --> Recruiting
- ||| Enrollment open: Threshold Suspend in Pediatrics at Home (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=300, Recruiting, Sponsor: Medtronic Diabetes
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jul 15, 2014
P1, N=20, Active, not recruiting, Sponsor: Tisch Multiple Sclerosis Research Center of New York
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS (clinicaltrials.gov) - Jul 15, 2014
P4, N=145, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New P2 trial: Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp (clinicaltrials.gov) - Jul 14, 2014
P2, N=22, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Jul 14, 2014
P1b, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Enrollment open: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 14, 2014
P2, N=75, Recruiting, Sponsor: Grifols Therapeutics Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Enrollment change, Trial primary completion date: NEO: An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=254, Active, not recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting N=154 --> 254 | Trial primary completion date: Oct 2012 --> Oct 2014
- |||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: RAPID-C: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 12, 2014
P3, N=400, Recruiting, Sponsor: UCB Pharma SA, Belgium
N=154 --> 254 | Trial primary completion date: Oct 2012 --> Oct 2014 Not yet recruiting --> Recruiting
- || decernotinib (VX-509) / Vertex
Trial primary completion date: 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate (clinicaltrials.gov) - Jul 12, 2014
P2, N=350, Active, not recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2013 --> Aug 2014
- | Trial completion: Accuracy Characterization Study (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=30, Completed, Sponsor: Abbott Diabetes Care
Trial primary completion date: Oct 2013 --> Aug 2014 Recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion: Rituximab for Autoimmune Retinopathy (clinicaltrials.gov) - Jul 12, 2014
P1, N=5, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed Active, not recruiting --> Completed
- teriflunomide / Generic mfg.
Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=50, Recruiting, Sponsor: University at Buffalo
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Nov 2014
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=198, Completed, Sponsor: Merck KGaA
Trial primary completion date: Jun 2014 --> Nov 2014 Trial primary completion date: Jul 2014 --> Apr 2014
- HEOR: PDMSLac: Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=39, Not yet recruiting, Sponsor: Florida State University
- ||| Clinical: Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=22639, Completed, Sponsor: Boehringer Ingelheim
- ||| Clinical: Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=121, Completed, Sponsor: Boehringer Ingelheim
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Evaluation of Brain Atrophy in CIS Patients on Avonex (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=180, Completed, Sponsor: University at Buffalo
Trial primary completion date: Jul 2014 --> Apr 2014 Active, not recruiting --> Completed
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Trial primary completion date, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=198, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014
- Trial primary completion date: Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jul 10, 2014
P2, N=28, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014 Trial primary completion date: Jul 2014 --> Dec 2014
- Trial initiation date: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 10, 2014
P2, N=20, Recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
Trial primary completion date: Jul 2014 --> Dec 2014 Initiation date: Dec 2013 --> Apr 2014
- ||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion: A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jul 10, 2014
P3, N=218, Completed, Sponsor: Genentech
Initiation date: Dec 2013 --> Apr 2014 Active, not recruiting --> Completed
- || Rixathon (rituximab biosimilar) / Kyowa Kirin, Novartis
Trial primary completion date: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=297, Recruiting, Sponsor: Sandoz
Active, not recruiting --> Completed Trial primary completion date: Apr 2012 --> Nov 2015
- Trial termination: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 8, 2014
P2, N=3, Terminated, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Trial primary completion date: Apr 2012 --> Nov 2015 Recruiting --> Terminated; Poor recruitment
- Enrollment change, Trial termination: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 8, 2014
P2, N=3, Terminated, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
Recruiting --> Terminated; Poor recruitment N=50 --> 3 | Recruiting --> Terminated; Poor recruitment
- ||| Rixathon (rituximab biosimilar) / Kyowa Kirin, Novartis
Enrollment change, Trial primary completion date: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=297, Recruiting, Sponsor: Sandoz
N=50 --> 3 | Recruiting --> Terminated; Poor recruitment N=164 --> 297 | Trial primary completion date: Apr 2012 --> Nov 2015